MedTrace Logo

Efficacy Study of GLYC-101 to Evaluate Outcomes After Post-laser Ablation

NCT00656474 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2021-10-28

Study results available
· View outcomes & findings →

Summary

Study is intended to evaluate safety and efficacy parameters in patients treated with GLYC-101 gel or placebo after laser ablation.

Conditions

  • Wounds

Interventions

DRUG

Placebo gel

Administration of Placebo gel on Day 1, 3 and 5 post ablation.

DRUG

GLYC-101 gel (1.0 %)

Administration on Day 1, 3 and 5 post laser ablation.

Sponsors & Collaborators

  • TR Therapeutics

    lead INDUSTRY

Principal Investigators

  • John Joseph, MD · CLINICAL TESTING CENTER of BEVERLY HILLS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2008-04-30
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00656474 on ClinicalTrials.gov